Skip to main content

Advertisement

Table 1 DUB inhibitors

From: The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics

Compound Reported activity/target Ref.
Inhibitors containing Michael acceptors
12Δ-PGJ2 UCHL3 [139]
15Δ-PGJ2 UCHL1 [139]
G5 Broad spectrum DUB inhibition [140]
b-AP15 USP14/UCH37 [141]
VLX1570 USP14/UCH37 [141]
AM146, RA-9 and RA-14 USP2a/USP2b/USP5/USP8 [143]
WP1130 USP5/USP9x/USP14/UCHL1/UCHL5 [144]
Eeyarestatin 1 Ataxin-3 [145]
Small inhibitors
AC17 USP14/UCH37 [142]
P022077 USP7 [146]
HBX 41, 108 USP7 [148]
HBX-19, 818 USP7 [149]
HBX-28, 258 USP7 [149]
P5091 USP7 [147]
Cpd 14 USP7/USP47 [150]
P22077 USP7/USP47 [151]
IU1 USP14 [139]
LDN-57444 UCHL1 [152]
LDN91946 UCHL1 [153]
LS1 UCHL3 [156]
PR-619 Broad spectrum DUB inhibition [157]
15-oxospiramilactone (S3) USP30 [158]
Clinical drugs
Pimozide USP1 [154]
Auranofin proteasome-associated DUBs [155]